MRK - Health Care Company Merck & Co Announces Acquisition of Harpoon Therapeutics | Benzinga
Merck & Co (NYSE:MRK) has announced an acquisition of Harpoon Therapeutics (NASDAQ:HARP) that is expected to be completed 2024-H1.
Under the terms of the agreement, Merck & Co has agreed to give Harpoon Therapeutics $680.00 million in cash in exchange for HARP stock.
About The Companies Involved
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor ...